The Experts below are selected from a list of 96 Experts worldwide ranked by ideXlab platform
Seied Mahdi Pourmortazavi - One of the best experts on this subject based on the ideXlab platform.
-
a novel chitosan polyethylene oxide nanofibrous mat designed for controlled co Release of Hydrocortisone and imipenem cilastatin drugs
International Journal of Pharmaceutics, 2016Co-Authors: Yousef Fazli, Zahra Shariatinia, Iraj Kohsari, Amir Reza Azadmehr, Seied Mahdi PourmortazaviAbstract:Abstract Antimicrobial chitosan–polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ∼70–200 nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ∼20–130 nm. For all of the nanofibrous mats, the water uptakes were the highest in acidic medium but they were decreased in the buffer and the least swellings were obtained in the alkaline environment. The drug incorporated mat preserved its bactericidal activity even after it was utilized in the Release experiment for 8 days in the PBS buffer. The Hydrocortisone Release was increased to 82% within first 12 h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
-
A novel chitosan-polyethylene oxide nanofibrous mat designed for controlled co-Release of Hydrocortisone and imipenem/cilastatin drugs.
International journal of pharmaceutics, 2016Co-Authors: Yousef Fazli, Zahra Shariatinia, Iraj Kohsari, Amir Reza Azadmehr, Seied Mahdi PourmortazaviAbstract:Antimicrobial chitosan-polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ∼70-200nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ∼20-130nm. For all of the nanofibrous mats, the water uptakes were the highest in acidic medium but they were decreased in the buffer and the least swellings were obtained in the alkaline environment. The drug incorporated mat preserved its bactericidal activity even after it was utilized in the Release experiment for 8days in the PBS buffer. The Hydrocortisone Release was increased to 82% within first 12h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
A Rubinstein - One of the best experts on this subject based on the ideXlab platform.
-
Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat.
Journal of controlled release : official journal of the Controlled Release Society, 2000Co-Authors: I Gliko-kabir, B Yagen, M Baluom, A RubinsteinAbstract:Targeting of drugs to the colon, following oral administration, can be accomplished by the use of modified, biodegradable polysaccharides as vehicles. In a previous study, a crosslinked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products (GGP) as possible colon-specific drug carriers was analyzed by studying (a) the Release kinetics of pre-loaded Hydrocortisone from GGP hydrogels into buffer solutions with, or without GG degrading enzymes (alpha-galactosidase and beta-mannanase) and (b) direct measurements of the polymers' degradation in the cecum of conscious rats. The effect of GG diet on alpha-galactosidase and beta-mannanase activity in the cecum of the rat and GGP degradation was also measured. It was found that the product GGP-0.1 (loosely crosslinked with 0.1 equivalents of STMP) was able to prevent the Release of 80% of its Hydrocortisone load for at least 6 h in PBS, pH=6.4. When a mixture of alpha-galactosidase and beta-mannanase was added to the buffer solution, an enhanced Hydrocortisone Release was observed. In-vivo degradation studies in the rat cecum showed that despite the chemical modification of GG, it retained its enzyme-degrading properties in a crosslinker concentration-dependent manner. Eight days of GG diet prior to the study increased alpha-galactosidase activity in the cecum of the rat three-fold, compared to its activity without the diet. However, this increase in the enzyme activity was unable to improve the degradation of the different GGP products. The overall alpha-galactosidase activity in the rat cecum was found to be extracellular, while the activity of beta-mannanase was found to be bacterial cell-wall associated. It is concluded that because CG crosslinked with STMP can be biodegraded enzymatically and is able to retard the Release of a low water-soluble drug, this polymer could potentially be used as a vehicle for colon-specific drug delivery.
-
Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat.
Journal of Controlled Release, 2000Co-Authors: I Gliko-kabir, B Yagen, M Baluom, A RubinsteinAbstract:Abstract Targeting of drugs to the colon, following oral administration, can be accomplished by the use of modified, biodegradable polysaccharides as vehicles. In a previous study, a crosslinked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products (GGP) as possible colon-specific drug carriers was analyzed by studying (a) the Release kinetics of pre-loaded Hydrocortisone from GGP hydrogels into buffer solutions with, or without GG degrading enzymes (α-galactosidase and β-mannanase) and (b) direct measurements of the polymers’ degradation in the cecum of conscious rats. The effect of GG diet on α-galactosidase and β-mannanase activity in the cecum of the rat and GGP degradation was also measured. It was found that the product GGP-0.1 (loosely crosslinked with 0.1 equivalents of STMP) was able to prevent the Release of 80% of its Hydrocortisone load for at least 6 h in PBS, pH=6.4. When a mixture of α-galactosidase and β-mannanase was added to the buffer solution, an enhanced Hydrocortisone Release was observed. In-vivo degradation studies in the rat cecum showed that despite the chemical modification of GG, it retained its enzyme-degrading properties in a crosslinker concentration-dependent manner. Eight days of GG diet prior to the study increased α-galactosidase activity in the cecum of the rat three-fold, compared to its activity without the diet. However, this increase in the enzyme activity was unable to improve the degradation of the different GGP products. The overall α-galactosidase activity in the rat cecum was found to be extracellular, while the activity of β-mannanase was found to be bacterial cell-wall associated. It is concluded that because CG crosslinked with STMP can be biodegraded enzymatically and is able to retard the Release of a low water-soluble drug, this polymer could potentially be used as a vehicle for colon-specific drug delivery.
Vitaliy V. Khutoryanskiy - One of the best experts on this subject based on the ideXlab platform.
-
Formulation of Carbopol®/Poly(2-ethyl-2-oxazoline)s Mucoadhesive Tablets for Buccal Delivery of Hydrocortisone
Polymers, 2018Co-Authors: Leire Ruiz-rubio, María Luz Alonso, Leyre Pérez-Álvarez, Rosa M. Alonso, José Luis Vilas, Vitaliy V. KhutoryanskiyAbstract:Poly(2-ethyl-2-oxazoline) has become an excellent alternative to the use of poly(ethylene glycol) in pharmaceutical formulations due to its valuable physicochemical and biological properties. This work presents a formulation of poorly-water soluble drug, Hydrocortisone, using interpolymer complexes and physical blends of poly(2-ethyl-2-oxazoline)s and two Carbopols® (Carbopol 974 and Carbopol 971) for oromucosal administration. The swelling, Hydrocortisone Release and mucoadhesive properties of a series of tablet formulations obtained by combination of different Carbopols with poly(2-ethyl-2-oxazoline)s of different molecular weights have been evaluated in vitro.
Yousef Fazli - One of the best experts on this subject based on the ideXlab platform.
-
Biocompatible Electrospun Nanofibrous Mats Designed for Controlled Co-Release of Hydrocortisone and Imipenem/Cilastatin Drugs
Eco-friendly and Smart Polymer Systems, 2020Co-Authors: Zahra Shariatinia, Yousef FazliAbstract:Antimicrobial chitosan–polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ~70–200 nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ~20–130 nm. The Hydrocortisone Release increased to 82% within first 12 h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
-
biocompatible electrospun nanofibrous mats designed for controlled co Release of Hydrocortisone and imipenem cilastatin drugs
International Seminar on Polymer Science and Technology, 2018Co-Authors: Zahra Shariatinia, Yousef FazliAbstract:Antimicrobial chitosan–polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ~70–200 nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ~20–130 nm. The Hydrocortisone Release increased to 82% within first 12 h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
-
a novel chitosan polyethylene oxide nanofibrous mat designed for controlled co Release of Hydrocortisone and imipenem cilastatin drugs
International Journal of Pharmaceutics, 2016Co-Authors: Yousef Fazli, Zahra Shariatinia, Iraj Kohsari, Amir Reza Azadmehr, Seied Mahdi PourmortazaviAbstract:Abstract Antimicrobial chitosan–polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ∼70–200 nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ∼20–130 nm. For all of the nanofibrous mats, the water uptakes were the highest in acidic medium but they were decreased in the buffer and the least swellings were obtained in the alkaline environment. The drug incorporated mat preserved its bactericidal activity even after it was utilized in the Release experiment for 8 days in the PBS buffer. The Hydrocortisone Release was increased to 82% within first 12 h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
-
A novel chitosan-polyethylene oxide nanofibrous mat designed for controlled co-Release of Hydrocortisone and imipenem/cilastatin drugs.
International journal of pharmaceutics, 2016Co-Authors: Yousef Fazli, Zahra Shariatinia, Iraj Kohsari, Amir Reza Azadmehr, Seied Mahdi PourmortazaviAbstract:Antimicrobial chitosan-polyethylene oxide (CS-PEO) nanofibrous mats containing ZnO nanoparticles (NPs) and Hydrocortisone-imipenem/cilastatin-loaded ZnO NPs were produced by electrospinning technique. The FE-SEM images displayed that the spherical ZnO NPs were ∼70-200nm in size and the CS-PEO nanofibers were very uniform and free of any beads which had average diameters within the range of ∼20-130nm. For all of the nanofibrous mats, the water uptakes were the highest in acidic medium but they were decreased in the buffer and the least swellings were obtained in the alkaline environment. The drug incorporated mat preserved its bactericidal activity even after it was utilized in the Release experiment for 8days in the PBS buffer. The Hydrocortisone Release was increased to 82% within first 12h while the Release rate of imipenem/cilastatin was very much slower so that 20% of the drug was Released during this period of time suggesting this nanofibrous mat is very suitable to inhibit inflammation (by Hydrocortisone) and infection (using imipenem/cilastatin antibiotic and ZnO NPs) principally for the wound dressing purposes.
I Gliko-kabir - One of the best experts on this subject based on the ideXlab platform.
-
Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat.
Journal of controlled release : official journal of the Controlled Release Society, 2000Co-Authors: I Gliko-kabir, B Yagen, M Baluom, A RubinsteinAbstract:Targeting of drugs to the colon, following oral administration, can be accomplished by the use of modified, biodegradable polysaccharides as vehicles. In a previous study, a crosslinked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products (GGP) as possible colon-specific drug carriers was analyzed by studying (a) the Release kinetics of pre-loaded Hydrocortisone from GGP hydrogels into buffer solutions with, or without GG degrading enzymes (alpha-galactosidase and beta-mannanase) and (b) direct measurements of the polymers' degradation in the cecum of conscious rats. The effect of GG diet on alpha-galactosidase and beta-mannanase activity in the cecum of the rat and GGP degradation was also measured. It was found that the product GGP-0.1 (loosely crosslinked with 0.1 equivalents of STMP) was able to prevent the Release of 80% of its Hydrocortisone load for at least 6 h in PBS, pH=6.4. When a mixture of alpha-galactosidase and beta-mannanase was added to the buffer solution, an enhanced Hydrocortisone Release was observed. In-vivo degradation studies in the rat cecum showed that despite the chemical modification of GG, it retained its enzyme-degrading properties in a crosslinker concentration-dependent manner. Eight days of GG diet prior to the study increased alpha-galactosidase activity in the cecum of the rat three-fold, compared to its activity without the diet. However, this increase in the enzyme activity was unable to improve the degradation of the different GGP products. The overall alpha-galactosidase activity in the rat cecum was found to be extracellular, while the activity of beta-mannanase was found to be bacterial cell-wall associated. It is concluded that because CG crosslinked with STMP can be biodegraded enzymatically and is able to retard the Release of a low water-soluble drug, this polymer could potentially be used as a vehicle for colon-specific drug delivery.
-
Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat.
Journal of Controlled Release, 2000Co-Authors: I Gliko-kabir, B Yagen, M Baluom, A RubinsteinAbstract:Abstract Targeting of drugs to the colon, following oral administration, can be accomplished by the use of modified, biodegradable polysaccharides as vehicles. In a previous study, a crosslinked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products (GGP) as possible colon-specific drug carriers was analyzed by studying (a) the Release kinetics of pre-loaded Hydrocortisone from GGP hydrogels into buffer solutions with, or without GG degrading enzymes (α-galactosidase and β-mannanase) and (b) direct measurements of the polymers’ degradation in the cecum of conscious rats. The effect of GG diet on α-galactosidase and β-mannanase activity in the cecum of the rat and GGP degradation was also measured. It was found that the product GGP-0.1 (loosely crosslinked with 0.1 equivalents of STMP) was able to prevent the Release of 80% of its Hydrocortisone load for at least 6 h in PBS, pH=6.4. When a mixture of α-galactosidase and β-mannanase was added to the buffer solution, an enhanced Hydrocortisone Release was observed. In-vivo degradation studies in the rat cecum showed that despite the chemical modification of GG, it retained its enzyme-degrading properties in a crosslinker concentration-dependent manner. Eight days of GG diet prior to the study increased α-galactosidase activity in the cecum of the rat three-fold, compared to its activity without the diet. However, this increase in the enzyme activity was unable to improve the degradation of the different GGP products. The overall α-galactosidase activity in the rat cecum was found to be extracellular, while the activity of β-mannanase was found to be bacterial cell-wall associated. It is concluded that because CG crosslinked with STMP can be biodegraded enzymatically and is able to retard the Release of a low water-soluble drug, this polymer could potentially be used as a vehicle for colon-specific drug delivery.